1,040 Shares in Penumbra, Inc. (NYSE:PEN) Acquired by Silver Oak Securities Incorporated

Silver Oak Securities Incorporated acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,040 shares of the company's stock, valued at approximately $278,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. RTW Investments LP increased its holdings in Penumbra by 8.4% in the fourth quarter. RTW Investments LP now owns 862,450 shares of the company's stock valued at $204,815,000 after purchasing an additional 66,700 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Penumbra by 47.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock valued at $167,913,000 after purchasing an additional 227,506 shares during the period. Bank of America Corp DE increased its holdings in Penumbra by 19.9% in the fourth quarter. Bank of America Corp DE now owns 346,528 shares of the company's stock valued at $82,293,000 after purchasing an additional 57,421 shares during the period. Dimensional Fund Advisors LP increased its holdings in Penumbra by 23.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 323,964 shares of the company's stock valued at $76,937,000 after purchasing an additional 60,764 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Penumbra by 7.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 321,046 shares of the company's stock valued at $87,045,000 after purchasing an additional 21,649 shares during the period. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Stock Down 0.3%

NYSE PEN traded down $0.66 during trading hours on Thursday, hitting $243.73. The company's stock had a trading volume of 358,956 shares, compared to its average volume of 453,908. Penumbra, Inc. has a 52 week low of $148.00 and a 52 week high of $310.00. The company has a market capitalization of $9.44 billion, a PE ratio of 229.93, a price-to-earnings-growth ratio of 2.21 and a beta of 0.47. The company has a current ratio of 6.30, a quick ratio of 3.68 and a debt-to-equity ratio of 0.02. The company's 50-day simple moving average is $266.21 and its two-hundred day simple moving average is $268.16.

Penumbra (NYSE:PEN - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. The firm had revenue of $324.14 million for the quarter, compared to analysts' expectations of $315.72 million. During the same quarter last year, the firm earned $0.41 EPS. The company's quarterly revenue was up 16.3% compared to the same quarter last year. Research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wells Fargo & Company increased their price target on Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Robert W. Baird increased their price target on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Stifel Nicolaus set a $318.00 price target on Penumbra and gave the stock a "buy" rating in a report on Thursday, April 24th. Wall Street Zen upgraded Penumbra from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 14th. Finally, Bank of America assumed coverage on Penumbra in a report on Friday, March 14th. They set a "buy" rating and a $320.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Penumbra has an average rating of "Moderate Buy" and an average target price of $305.07.

Insider Activity

In other Penumbra news, CEO Adam Elsesser sold 16,650 shares of Penumbra stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $289.37, for a total transaction of $4,818,010.50. Following the transaction, the chief executive officer owned 75,237 shares of the company's stock, valued at $21,771,330.69. This trade represents a 18.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Maggie Yuen sold 2,000 shares of Penumbra stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $299.01, for a total transaction of $598,020.00. Following the completion of the sale, the chief financial officer directly owned 13,957 shares in the company, valued at $4,173,282.57. This trade represents a 12.53% decrease in their position. The disclosure for this sale can be found here. Insiders sold 114,810 shares of company stock worth $31,734,215 in the last quarter. 4.20% of the stock is owned by corporate insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.